Company Overview
Skye Bioscience (Nasdaq: SKYE) is a biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Backed by specialist life science investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). Skye expects interim and topline data from its Phase 2 study in 2025.
Latest Financial Results
Q3 2024
Quarter Ended Sep 30, 2024
For complete information regarding our financials, see our periodic filings
IR Contacts
Company
Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130
Investor Relations
SKYE Investor Relations
T: (858) 410-0266
ir@skyebioscience.com
Transfer Agent
ClearTrust, LLC
16540 Pointe Village Dr.
Suite 210
Lutz, FL 33558
T: 813-235-4490
www.ClearTrustOnline.com
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.